7 However, large-scale clinical trials worldwide currently use rt-PA for hematoma fibrinolysis because urokinase was discontinued from the US market in 1999 due to the risk of transmitting infectious pathogens. However, the optimal dose and the time window of use of urokinase and rt-PA remain ...